SCHEMBL1577585

SCHEMBL1577585

CS(=O)(=O)c1cccc(OCc2ccc(C3CCN(C(=O)O)CC3)cn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.43
DRD2 P14416 2/20 0.42
SIGMAR1 Q99720 1/20 0.41
GPR119 Q8TDV5 3/20 0.41
F10 P00742 2/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
PRMT5 O14744 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALOX5AP P20292 1/20 0.39
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
JAK2 O60674 1/20 0.37
PTK2 Q05397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1577527 0.88 GPR119 (0.48) EPHX2GPR119PRMT5
SCHEMBL1577766 0.87 SPHK1 (0.47) GPR119PRMT5NPC1TP53MAPT
SCHEMBL1577389 0.86 CPT2 (0.41) DRD2F10PRMT5NPC1TP53
SCHEMBL1577335 0.85 PRMT5 (0.42) F10PRMT5NPC1TP53MAPT
SCHEMBL1577940 0.84 ALDH1A1 (0.40) EPHX2GPR119NPC1SMN1; SMN2
SCHEMBL1578092 0.84 GPR119 (0.39) GPR119PRMT5NPC1RAB9AKMT2A
SCHEMBL1577928 0.84 TRPC6 (0.42) GPR119NPC1RAB9A
SCHEMBL1577750 0.83 NPC1 (0.42) EPHX2DRD2GPR119NPC1RAB9A
SCHEMBL1578009 0.83 NPC1 (0.42) EPHX2GPR119NPC1RAB9AKMT2A
SCHEMBL1577293 0.83 DPP4 (0.41) EPHX2DRD2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140018537-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2014-01-16 US disclosed
US-8536176-B2 GPR119 agonist NIPPON CHEMIPHAR CO., LTD. (JP) 2013-09-17 US disclosed
US-20110137032-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2011-06-09 US disclosed
EP-2311822-A1 GPR119 AGONIST Nippon Chemiphar Co., Ltd. (JP) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018537-A1 GPR119 AGONIST GPR119, GPR27, GPR52 EPHX2 3213/4885DRD2 182/4885SIGMAR1 445/4885
US-20110137032-A1 GPR119 AGONIST GPR119, GPR27, GPR52 EPHX2 3213/4885DRD2 182/4885SIGMAR1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.